<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
<channel>
<title>
<![CDATA[ Fierce Pharma ]]>
</title>
<description>
<![CDATA[ Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance. ]]>
</description>
<link>https://www.fiercepharma.com/</link>
<image>
<url>https://qtxasset.com/quartz/qcloud5/fiercefavicon.ico</url>
<title>Fierce Pharma</title>
<link>https://www.fiercepharma.com/</link>
</image>
<generator>https://rss.app</generator>
<lastBuildDate>Wed, 18 Jun 2025 09:48:27 GMT</lastBuildDate>
<atom:link href="https://rss.app/feeds/TICvGA7W7zZIYi5d.xml" rel="self" type="application/rss+xml"/>
<language>
<![CDATA[ en ]]>
</language>
<item>
<title>
<![CDATA[ Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/Featured%20Images%20-%20Fierce%20Healthcare%20-%202025-05-21T151739.628.jpg?VersionId=QDlsQci3q6SiykgE9YNO0weKf3Y_yrMZ" style="width: 100%;" /><div>Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a legislative loophole that drugmakers are allegedly lobbying to retain. | Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a legislative loophole that drugmakers are allegedly lobbying to retain.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/lawmakers-refresh-tax-dodging-accusations-against-pharma-targeting-pfizer-abbvie-and-others</link>
<guid isPermaLink="false">069b54a8729b8bd4a887a8a60a03f33b</guid>
<dc:creator>
<![CDATA[ Angus Liu ]]>
</dc:creator>
<pubDate>Tue, 17 Jun 2025 20:56:05 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/Featured%20Images%20-%20Fierce%20Healthcare%20-%202025-05-21T151739.628.jpg?VersionId=QDlsQci3q6SiykgE9YNO0weKf3Y_yrMZ"/>
</item>
<item>
<title>
<![CDATA[ Ousted ACIP members fire back at RFK Jr.'s 'destabilizing' decisions for US vaccine policy ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/Featured%20Images%20-%20Fierce%20Healthcare%20-%202025-03-26T100147.764.jpg?VersionId=j5c.NUVs.Ff0j7PJp2nDpX3EdDSnsPUh" style="width: 100%;" /><div>Following HHS secretary Robert F. | Following HHS secretary Robert F. Kennedy Jr.’s decision last week to purge the CDC’s Advisory Committee on Immunization Practices and appoint his own replacements, the 17 ousted experts are hitting back at the arguments behind the cull.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/ousted-acip-members-fire-back-rfk-jrs-destabilizing-decisions-us-vaccine-policy</link>
<guid isPermaLink="false">9b3b85b37af8e39435acb75ad56bbb73</guid>
<dc:creator>
<![CDATA[ Fraiser Kansteiner ]]>
</dc:creator>
<pubDate>Tue, 17 Jun 2025 18:32:17 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/Featured%20Images%20-%20Fierce%20Healthcare%20-%202025-03-26T100147.764.jpg?VersionId=j5c.NUVs.Ff0j7PJp2nDpX3EdDSnsPUh"/>
</item>
<item>
<title>
<![CDATA[ IPG Health outfits dominate another Cannes agency showdown, with Real Chemistry and Ogilvy Health earning accolades, too ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/canneslionstrophy.jpg?VersionId=GcioSKRGd.L8G1FX5NmKrb0QWbOVoCEW" style="width: 100%;" /><div>Each year in mid-June, advertising agencies that work behind the scenes to execute drug ads are rewarded with their moment in the spotlight as the biggest award event in advertising plays out in Ca | Cannes Lions named FCB Health the Healthcare Network of the Year, while AREA 23 is the Healthcare Agency of the year. Both agencies are arms of IPG Health.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/marketing/ipg-health-agencies-dominate-another-cannes-agency-award-showdown-real-chemistry-and</link>
<guid isPermaLink="false">f886dc6a02234e27bfb3b35e466cbf96</guid>
<dc:creator>
<![CDATA[ Zoey Becker ]]>
</dc:creator>
<pubDate>Tue, 17 Jun 2025 18:28:17 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/canneslionstrophy.jpg?VersionId=GcioSKRGd.L8G1FX5NmKrb0QWbOVoCEW"/>
</item>
<item>
<title>
<![CDATA[ In setback for biopharma, Senate version of Trump's tax bill drops Orphan Cures Act ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/Capitol.jpg?VersionId=AFhgRf63sszBpsQ7IlkNCNDTxTtSJim0" style="width: 100%;" /><div>The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend an Inflation Reduction Act (IRA) provision currently affecting treatment | The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend an Inflation Reduction Act provision currently affecting treatments for rare diseases.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/orphan-drug-fix-ira-dropped-senate-version-big-beautiful-bill-setback-biopharma</link>
<guid isPermaLink="false">29bc7362ab857b2f858c7b8b9761a809</guid>
<dc:creator>
<![CDATA[ Angus Liu ]]>
</dc:creator>
<pubDate>Tue, 17 Jun 2025 15:30:21 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/Capitol.jpg?VersionId=AFhgRf63sszBpsQ7IlkNCNDTxTtSJim0"/>
</item>
<item>
<title>
<![CDATA[ Trump rekindles pharmaceutical tariff threat, suggesting import duties could come 'very soon': Reuters ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-2197351521.jpg?VersionId=lviRiiy6I0bXXgebONwk_cgOUD4yGwVE" style="width: 100%;" /><div>With the industry in a holding pattern, President Donald Trump is again beating the drum for pharmaceutical import tariffs—though the exact nature and timing of their implementation remains unclear | With the industry in a holding pattern, President Donald Trump is again beating the drum for pharmaceutical import tariffs—though the exact nature and timing of their implementation remains unclear as ever.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/manufacturing/pharma-stocks-slide-trump-renews-tariff-threats-reuters</link>
<guid isPermaLink="false">fc346e490277dfcfb1ea67ff33247d0a</guid>
<dc:creator>
<![CDATA[ Fraiser Kansteiner ]]>
</dc:creator>
<pubDate>Tue, 17 Jun 2025 15:21:00 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-2197351521.jpg?VersionId=lviRiiy6I0bXXgebONwk_cgOUD4yGwVE"/>
</item>
<item>
<title>
<![CDATA[ With FDA nod for HAE drug Andembry, CSL set to compete with Takeda's Takhzyro ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/ANDEMBRY3.jpg?VersionId=gWgco.U5tuhO301XyrDe2IVYCkzdy8Wh" style="width: 100%;" /><div>After gaining approvals in Japan, Europe and the U.K. | With the FDA's approval of hereditary angioedema preventative treatment Andembry, CSL is ready to take on Takeda’s blockbuster Takhzyro and BioCryst Pharmaceuticals’ fast-rising Orladeyo in a competitive market to treat patients with the rare genetic condition.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/fda-nod-hae-treatment-andembry-csl-set-compete-takedas-blockbuster-takhzyro</link>
<guid isPermaLink="false">33a7d939f753320070e7d398c30f4af8</guid>
<dc:creator>
<![CDATA[ Kevin Dunleavy ]]>
</dc:creator>
<pubDate>Tue, 17 Jun 2025 15:10:51 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/ANDEMBRY3.jpg?VersionId=gWgco.U5tuhO301XyrDe2IVYCkzdy8Wh"/>
</item>
<item>
<title>
<![CDATA[ Shrinking budgets and rising targets pile pressure on pharma marketers: survey ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1077553686.jpg?VersionId=_mZ3qxbJO1Ugb9X0vRNwmkH9eXutAtY." style="width: 100%;" /><div>European marketers are feeling the squeeze, with a combination of shrinking budgets, rising targets and tightening compliance requirements piling on the pressure,</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/marketing/shrinking-budgets-and-rising-targets-pile-pressure-pharma-marketers-survey</link>
<guid isPermaLink="false">b40877aba3a96b03ce4d4cf4d228b909</guid>
<dc:creator>
<![CDATA[ Nick Paul Taylor ]]>
</dc:creator>
<pubDate>Tue, 17 Jun 2025 14:53:25 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1077553686.jpg?VersionId=_mZ3qxbJO1Ugb9X0vRNwmkH9eXutAtY."/>
</item>
<item>
<title>
<![CDATA[ Pharma roars onto the Cannes Pharma Lions podium, with Viatris winning Grand Prix and Biogen taking home Gold ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/canneslionstrophy.jpg?VersionId=GcioSKRGd.L8G1FX5NmKrb0QWbOVoCEW" style="width: 100%;" /><div>With Viatris taking home the biggest prize at this year’s Cannes Pharma Lions award and Biogen winning Gold, pharma is making a comeback. | This year's Pharma Lions awards at the Cannes Lions International Festival of Creativity saw the Grand Prix prize going to to Viatris and its "Make Love Last" Viagra campaign.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/marketing/pharma-represents-cannes-pharma-lions-podium-viatris-winning-grand-prix-and-biogen-taking</link>
<guid isPermaLink="false">be3f291afa9fde63cb34a770d052f94d</guid>
<dc:creator>
<![CDATA[ Zoey Becker ]]>
</dc:creator>
<pubDate>Tue, 17 Jun 2025 14:30:00 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/canneslionstrophy.jpg?VersionId=GcioSKRGd.L8G1FX5NmKrb0QWbOVoCEW"/>
</item>
<item>
<title>
<![CDATA[ Roche, AbbVie say trial of Venclexta in patients with myelodysplastic syndromes falls short ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1592028647/Venclexta.png/Venclexta.png?VersionId=InsXaslcbOm1t2TNfl9uKGeuYGbJBAlQ" style="width: 100%;" /><div>Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood cancer treatment Venclexta. | Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood cancer treatment Venclexta.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/roche-abbvie-trial-venclexta-patients-myelodysplastic-syndromes-falls-short</link>
<guid isPermaLink="false">4efb6327d944b713dc007de984816cd8</guid>
<dc:creator>
<![CDATA[ Kevin Dunleavy ]]>
</dc:creator>
<pubDate>Mon, 16 Jun 2025 20:23:41 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1592028647/Venclexta.png/Venclexta.png?VersionId=InsXaslcbOm1t2TNfl9uKGeuYGbJBAlQ"/>
</item>
<item>
<title>
<![CDATA[ Veranova, Enzene plot new biologic manufacturing expansions on East Coast ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1371315657.jpg?VersionId=3wNvVE1SIuzeOVyW8ZSN0IaOEBOn5aGU" style="width: 100%;" /><div>Amid a spate of high-profile investments in U.S. pharmaceutical production, two contract manufacturers are getting in on the action with an emphasis on biologic drugs. | Amid a spate of investments in U.S. pharmaceutical production, two contract manufacturers are joining the fray with separate biologics expansions.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/manufacturing/manufacturers-veranova-enzene-announce-separate-biologics-expansions-east-coast</link>
<guid isPermaLink="false">7b09506232b98a3050643cbc1a606055</guid>
<dc:creator>
<![CDATA[ Fraiser Kansteiner ]]>
</dc:creator>
<pubDate>Mon, 16 Jun 2025 20:05:00 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1371315657.jpg?VersionId=3wNvVE1SIuzeOVyW8ZSN0IaOEBOn5aGU"/>
</item>
<item>
<title>
<![CDATA[ Supernus acquires struggling Sage for $561M, taking a flier on depression drug Zurzuvae ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1134270327.jpg?VersionId=CPFh1Nmt55XpyMoh9.GDDKCPnQAQWrFm" style="width: 100%;" /><div>Neurology specialist Supernus Pharmaceuticals will</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/supernus-acquires-struggling-sage-561m-taking-flier-postpartum-depression-drug-zurzuvae</link>
<guid isPermaLink="false">323651fded34a5d0f34afeea41463a84</guid>
<dc:creator>
<![CDATA[ Kevin Dunleavy ]]>
</dc:creator>
<pubDate>Mon, 16 Jun 2025 15:52:05 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1134270327.jpg?VersionId=CPFh1Nmt55XpyMoh9.GDDKCPnQAQWrFm"/>
</item>
<item>
<title>
<![CDATA[ Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1642080437/sarepta%20building.jpg/sarepta%20building.jpg?VersionId=DbRW8o5T3zGk93SbxdXhAOpzBEQnQ63h" style="width: 100%;" /><div>A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/sarepta-records-second-death-after-dmd-gene-therapy-elevidys-stops-dosing-half-patients</link>
<guid isPermaLink="false">5341c328cabfa02ce401579d439c1b97</guid>
<dc:creator>
<![CDATA[ Angus Liu ]]>
</dc:creator>
<pubDate>Mon, 16 Jun 2025 14:58:37 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1642080437/sarepta%20building.jpg/sarepta%20building.jpg?VersionId=DbRW8o5T3zGk93SbxdXhAOpzBEQnQ63h"/>
</item>
<item>
<title>
<![CDATA[ AstraZeneca touts early Ultomiris survival data in children living with rare post-transplant complication ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/AstraZeneca_4.jpg?VersionId=3QzvLhNI3gL.iCOFTMNw1wqnJmdd0MCU" style="width: 100%;" /><div>Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark. | In initial results from a phase 3 trial, Ultomiris helped pediatric patients with thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT) achieve an overall survival rate of 87.2% at 26 weeks, AstraZeneca said. The data could help position Ultomiris to help address a potentially deadly post-transplant complication with no targeted treatment options.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/az-touts-early-ultomiris-survival-data-kids-living-rare-post-transplant-complication</link>
<guid isPermaLink="false">f39f57a1ef9d0417f04a484a4218f5ef</guid>
<dc:creator>
<![CDATA[ Fraiser Kansteiner ]]>
</dc:creator>
<pubDate>Mon, 16 Jun 2025 14:32:00 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/AstraZeneca_4.jpg?VersionId=3QzvLhNI3gL.iCOFTMNw1wqnJmdd0MCU"/>
</item>
<item>
<title>
<![CDATA[ Precision medicine’s next frontier: unlocking the power of biospecimens ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/public/brightcove/videos/images/posters/image_3204.jpg?VersionId=9X5SOd0YW8fSCrvAv7RBR5JwSOM6OF8." style="width: 100%;" /><div>In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher Scientific, unpacks the evolving landscape of precision therapeutic and di | Austin Read of Thermo Fisher Scientific discusses how combining biospecimens with real-world data is advancing diagnostics, treatment and the future of patient care.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/precision-medicines-next-frontier-unlocking-power-biospecimens</link>
<guid isPermaLink="false">645674f8a8daa2df19feb8d8066940f6</guid>
<dc:creator>
<![CDATA[ Questex Partner ]]>
</dc:creator>
<pubDate>Mon, 16 Jun 2025 12:00:00 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/public/brightcove/videos/images/posters/image_3204.jpg?VersionId=9X5SOd0YW8fSCrvAv7RBR5JwSOM6OF8."/>
</item>
<item>
<title>
<![CDATA[ FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/FDA%20STOP.jpg?VersionId=33eo0BnHveO4wxsGma8uhcfRqK5hZ2xH" style="width: 100%;" /><div>KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision-making, as the agency apparently blames a “heavy workload” for pushing back a PDUFA date. | KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision making, as the agency blames a “heavy workload” for pushing back a PDUFA date.</div></div> ]]>
</description>
<link>https://www.fiercebiotech.com/biotech/fdas-heavy-workload-blamed-delays-kalvistas-angioedema-drug-approval-decision</link>
<guid isPermaLink="false">73b32ea1d0b0f89ff3fdecbd5a4da0b5</guid>
<dc:creator>
<![CDATA[ James Waldron ]]>
</dc:creator>
<pubDate>Mon, 16 Jun 2025 08:33:45 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/FDA%20STOP.jpg?VersionId=33eo0BnHveO4wxsGma8uhcfRqK5hZ2xH"/>
</item>
<item>
<title>
<![CDATA[ Big Pharma's 10 highest-paid CEOs of 2024 ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1490494819.jpg?VersionId=5MWX6_RS7ij4hV3m3dZVUFyPDz8HYl38" style="width: 100%;" /><div>While many familiar names appear on Fierce’s 2024 pharma CEO pay ladder, multiple executives have rubber banded across the rankings, and the top spot has gone to a dark horse contender through a bit of stock option bravado.Still, the pay packages handed out for last year’s work seem to further cement a new status quo in the realm of CEO compensation, as several recently appointed leaders settle into their roles and companies establish their market positions heading into the second half of the decade.  | The pay packages handed out for last year’s work seem to further cement a new status quo in the realm of CEO compensation, as several recently appointed pharma leaders settle into their roles and companies establish their market positions heading into the second half of the decade.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/special-reports/big-pharmas-10-highest-paid-ceos-2024</link>
<guid isPermaLink="false">f2cbe88e2a7cb2c498715c0e464a9690</guid>
<dc:creator>
<![CDATA[ Kevin Dunleavy ]]>
</dc:creator>
<pubDate>Mon, 16 Jun 2025 07:00:00 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1490494819.jpg?VersionId=5MWX6_RS7ij4hV3m3dZVUFyPDz8HYl38"/>
</item>
<item>
<title>
<![CDATA[ Biogen leads Cannes Lions Pharma shortlist, with BMS, Novartis cracking Health & Wellness category ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/canneslionstrophy.jpg?VersionId=GcioSKRGd.L8G1FX5NmKrb0QWbOVoCEW" style="width: 100%;" /><div>Biogen has emerged as a potential frontrunner at the Cannes Lions International Festival of Creativity, snagging four spots on the Pharma shortlist for its work on Friedreich’s ataxia. | Biogen has emerged as a frontrunner at the Cannes Lions International Festival of Creativity, snagging four spots on the Pharma shortlist for its work on Friedreich’s ataxia. But the biotech was absent from the Health & Wellness category, where Bristol Myers Squibb and Novartis led pharma representation.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/marketing/biogen-leads-cannes-lions-pharma-shortlist-bms-novartis-cracking-health-wellness-category</link>
<guid isPermaLink="false">cd42b03876a0df6f8cca1d9151c2790b</guid>
<dc:creator>
<![CDATA[ Nick Paul Taylor ]]>
</dc:creator>
<pubDate>Mon, 16 Jun 2025 06:14:24 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/canneslionstrophy.jpg?VersionId=GcioSKRGd.L8G1FX5NmKrb0QWbOVoCEW"/>
</item>
<item>
<title>
<![CDATA[ Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/Merck_0.jpg?VersionId=jMiuL6RVRqUWJHhfWs5y3W9xPAhgP07D" style="width: 100%;" /><div>Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. | Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the indication is limited to PD-L1-positive disease.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/merck-keytruda-wins-breakthrough-head-and-neck-cancer-nod-around-surgery-limitation</link>
<guid isPermaLink="false">51d707c4e8bd4100a5230f47bb1fc98c</guid>
<dc:creator>
<![CDATA[ Angus Liu ]]>
</dc:creator>
<pubDate>Fri, 13 Jun 2025 14:50:25 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/Merck_0.jpg?VersionId=jMiuL6RVRqUWJHhfWs5y3W9xPAhgP07D"/>
</item>
<item>
<title>
<![CDATA[ Sens. Sanders, King propose legislation to ban direct-to-consumer ads for prescription drugs ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/SANDERSRFK.jpg?VersionId=YNs_7Ek2KPa0ddjpTxZrhCXxzpmOWHq_" style="width: 100%;" /><div>Independent Sens. | Independent Sens. Bernie Sanders of Vermont and Angus King of Maine have introduced a bill that would ban pharmaceutical companies from advertising directly to consumers. The End Prescription Drug Ads Now Act would prohibit drugmakers from promoting prescription drugs through television, radio, print, digital platforms and social media.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/marketing/sens-sanders-king-propose-legislation-would-ban-dtc-pharma-ads</link>
<guid isPermaLink="false">0d0f40a0328d135108cdc4c737dbacd5</guid>
<dc:creator>
<![CDATA[ Kevin Dunleavy ]]>
</dc:creator>
<pubDate>Fri, 13 Jun 2025 14:31:57 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/SANDERSRFK.jpg?VersionId=YNs_7Ek2KPa0ddjpTxZrhCXxzpmOWHq_"/>
</item>
<item>
<title>
<![CDATA[ Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN Entresto feud ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/AsiaMap.jpg?VersionId=LfBUS40Bp.PUirO_cA8zF4Daq7mjFKTe" style="width: 100%;" /><div>Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease IgAN. Novartis is pressing for a speedy ruling in its Entresto patent litigation against MSN Pharmaceuticals.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/pfizer-ceo-talks-bispecific-deal-otsuka-kidney-disease-win-novartis-msn-entresto-feud</link>
<guid isPermaLink="false">f6c8bb87c0916e0721b195c077234b81</guid>
<dc:creator>
<![CDATA[ Angus Liu ]]>
</dc:creator>
<pubDate>Fri, 13 Jun 2025 13:18:11 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/AsiaMap.jpg?VersionId=LfBUS40Bp.PUirO_cA8zF4Daq7mjFKTe"/>
</item>
<item>
<title>
<![CDATA[ UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1168877430.jpg?VersionId=yMkPZNbj3vX3TLiJZEWEYfbKnwP1nLyL" style="width: 100%;" /><div>Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. | Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), standing to replace the current surgical standard-of-care.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/urogens-zusduri-wins-fdas-blessing-first-therapy-certain-bladder-cancer-patients-despite</link>
<guid isPermaLink="false">913324045979dd6f68ed856687e9a19b</guid>
<dc:creator>
<![CDATA[ Zoey Becker ]]>
</dc:creator>
<pubDate>Fri, 13 Jun 2025 12:56:50 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1168877430.jpg?VersionId=yMkPZNbj3vX3TLiJZEWEYfbKnwP1nLyL"/>
</item>
<item>
<title>
<![CDATA[ Regulatory tracker: Moderna's RSV vaccine picks up wider FDA nod ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-2169470466.jpg?VersionId=Kj.qshvtYjs8G6V5RoFQIhlX.DvWuLv0" style="width: 100%;" /><div>Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2025</link>
<guid isPermaLink="false">ae623ee40211f7461ad043d3bc70217a</guid>
<dc:creator>
<![CDATA[ Kevin Dunleavy ]]>
</dc:creator>
<pubDate>Fri, 13 Jun 2025 11:45:00 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-2169470466.jpg?VersionId=Kj.qshvtYjs8G6V5RoFQIhlX.DvWuLv0"/>
</item>
<item>
<title>
<![CDATA[ ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30% ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1489208701.jpg?VersionId=XfMI2vbUhb8riegFZ2AAeW455NCShYjq" style="width: 100%;" /><div>After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. research site and laying off 30% of its workforce. | After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. R&D site and laying off 30% of its workforce.</div></div> ]]>
</description>
<link>https://www.fiercebiotech.com/biotech/adc-shutters-uk-rd-site-culls-several-preclinical-programs-and-trims-workforce-30</link>
<guid isPermaLink="false">d585afee47f51187c42dc26de30f62d9</guid>
<dc:creator>
<![CDATA[ Gabrielle Masson ]]>
</dc:creator>
<pubDate>Thu, 12 Jun 2025 19:00:56 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1489208701.jpg?VersionId=XfMI2vbUhb8riegFZ2AAeW455NCShYjq"/>
</item>
<item>
<title>
<![CDATA[ UCB touts plan for 'major' US investment to boost biologics capacity ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1612820538/UCBFlag.jpg?VersionId=4CeuMU0x3XBZ6QIyRUc71_p3.S7eRCRD" style="width: 100%;" /><div>Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S. spending pledges from some of the world's largest pharmaceutical companies. | Belgium's UCB is adding its name to the mix of drugmakers planning to grow their manufacturing footprints in the U.S.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/manufacturing/ucb-touts-plan-major-us-investment-boost-biologics-capacity</link>
<guid isPermaLink="false">7aef3de4bbf0e7199fb961c12cbbdf3c</guid>
<dc:creator>
<![CDATA[ Eric Sagonowsky ]]>
</dc:creator>
<pubDate>Thu, 12 Jun 2025 17:34:01 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1612820538/UCBFlag.jpg?VersionId=4CeuMU0x3XBZ6QIyRUc71_p3.S7eRCRD"/>
</item>
<item>
<title>
<![CDATA[ Bristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum ]]>
</title>
<description>
<![CDATA[ <div><img src="https://qtxasset.com/quartz/qcloud5/media/image/Boerner.jpg?VersionId=suH70PGUurLcjpwrlWyWxGxy2inpwFpA" style="width: 100%;" /><div>Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem. | Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem following a phase 3 flop and "moderating" new-to-brand prescription growth. But the company's top executives don't see things that way.</div></div> ]]>
</description>
<link>https://www.fiercepharma.com/pharma/bristol-myers-ceo-stays-bullish-cobenfy-despite-trial-flop-sign-slowing-momentum</link>
<guid isPermaLink="false">4dbaaf07c029aa88436a3bf3d5700102</guid>
<dc:creator>
<![CDATA[ Angus Liu ]]>
</dc:creator>
<pubDate>Thu, 12 Jun 2025 16:43:46 GMT</pubDate>
<media:content medium="image" url="https://qtxasset.com/quartz/qcloud5/media/image/Boerner.jpg?VersionId=suH70PGUurLcjpwrlWyWxGxy2inpwFpA"/>
</item>
</channel>
</rss>
